Real world (RW) use and outcomes of regorafenib (REG) flexible dosing in patients (pts) with metastatic colorectal cancer (mCRC) in Europe

被引：1

作者：

Peeters, Marc

Chibaudel, Benoist

Barzi, Afsaneh

Ostojic, Helene

Pan, Xiaoyun

Yasuda, Marie

Chen, Chi-Chang

Multani, Jasjit

Casey, Vicky

Vassilev, Zdravko

机构：

[1] Antwerp Univ, Univ Antwerp Hosp, Edegem, Belgium

[2] Fdn Cognacq Jay, Hop Franco Britann, Levallois Perret, France

[3] City Hope AccessHope, Med Oncol & Therapeut, Duarte, CA USA

[4] Bayer Consumer Care AG, Basel, Switzerland

[5] Bayer HealthCare Pharmaceut Inc, Real World Evidence Oncol, Whippany, NJ USA

[6] IQVIA Inc, Wayne, PA USA

[7] IQVIA Inc, Falls Church, VA USA

[8] IQVIA, London, England

[9] Bayer HealthCare Pharmaceut, Whippany, NJ USA

来源：

关键词：

D O I：

10.1200/JCO.2024.42.3_suppl.47

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：47 / 47

页数：1